SECTION 1. IDENTIFICATION

Product identifier used on th	e label	
Other means of identification	 Esperoct® [antihemore (recombinant), glycop None reported. 	
Recommended use of the ch	emical and restrictions on use	
Chemical family	Pharmaceutical Restriction on use: None knowrPure substance	
Name, address, and telep of the supplier:	hone number	Name, address, and telephone number of the manufacturer:
Novo Nordisk Inc.		Refer to supplier
800 Scudders Mill Road Plainsboro, NJ, USA 08536		
Supplier's Telephone #	: 1-800-727-6500	
24 Hr. Emergency Tel #	: 1-800-727-6500	
SECTION 2 HAZADDS ID	ENTIFICATION	

SECTION 2. HAZARDS IDENTIFICATION

Classification of the chemical

This material is not classified as hazardous under U.S. OSHA regulations (29CFR 1910.1200) (Hazcom 2012) and Canadian WHMIS regulations (Hazardous Products Regulations) (WHMIS 2015).

Label elements

Hazard pictogram(s)

None required under U.S. OSHA Hazcom 2012 and Canadian WHMIS 2015 regulations.

Signal Word

None required under U.S. OSHA HazCom 2012 and Canadian WHMIS 2015 regulations.

Hazard statement(s)

None required under OSHA HazCom2012 and 2015 Canadian WHMIS regulations.

Precautionary statement(s)

None required under U.S. OSHA HazCom 2012 and Canadian WHMIS 2015 regulations.

Other hazards

Other hazards which do not result in classification: Contact with eyes may cause irritation. Prolonged or repeated contact with skin may cause irritation in some cases.

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. Your needs may vary depending upon the potential for exposure in your workplace. The precautionary statements, warnings and hazards included herein may not apply in all cases, such as when the product or device is in its final form and being used to treat the approved medical condition(s) while under the care of a licensed medical professional and in accordance with the FDA-approved Prescribing Information. Refer to FDA-approved Prescribing Information for final marketed products containing Lyophilized N8-GP and excipients with regard to special storage, handling and administration requirements in the clinical setting.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Chemical name	Common name and synonyms	<u>CAS #</u>	Concentration (% by weight)	
Lyophilized N8-GP and excipients	Not available.	N/Av	100.00	

Page 1 of 8

SECTION 4. FIRST-AID MEASURES

Description of first aid	l measures
Ingestion	 Rinse mouth thoroughly and then drink plenty of water. Do NOT induce vomiting. See medical advice in case of persistent discomfort.
Inhalation	 Seek fresh air. Seek medical advice in case of persistent discomfort.
Skin contact	Remove contaminated clothes immediately. Wash skin with soap and water. Seek
	medical advice in case of persistent discomfort.
Eye contact	 Flush immediately with water (preferably using eye wash equipment) for at least 5 minutes. Open eye wide. Remove any contact lenses. Seek medical advice if irritation continues.
Most important sympt	oms and effects, both acute and delayed
	None known or reported by the manufacturer.
Indication of any imme	ediate medical attention and special treatment needed
	: None reported by the manufacturer.
SECTION 5. FIRE-F	IGHTING MEASURES
Extinguishing media	
Suitable extinguishir	
	: Use media suitable to the surrounding fire such as water fog or fine spray, alcohol
Unsuitable extinguis	foams, carbon dioxide and dry chemical.
eneeneere en igele	: Do not use a solid water stream as it may scatter and spread fire.
Special hazards arisin	g from the substance or mixture / Conditions of flammability
•	None known or reported by the manufacturer.
Flammability classification	ation (OSHA 29 CFR 1910.106)
	: Not flammable.
Hazardous combustio	n products
	: Carbon oxides and other irritating fumes and smoke.
Special protective equipment Protective equipment	ipment and precautions for firefighters tfor fire-fighters
	: None known or reported by the manufacturer.
Special fire-fighting	procedures
	: Evacuate personnel to safe areas. Move containers from fire area if safe to do so. Water spray may be useful in cooling equipment exposed to heat and flame. Dike for water control. Avoid release to the environment.
SECTION 6. ACCID	ENTAL RELEASE MEASURES
Personal precautions,	protective equipment and emergency procedures
	: None known or reported by the manufacturer.
Environmental precau	tions : None known or reported by the manufacturer.
Methods and material	for containment and cleaning up
	: Use sand, sawdust, earth, vermiculite, diatomaceous earth to contain and collect

Use sand, sawdust, earth, vermiculite, diatomaceous earth to contain and collect non-combustible absorbent materials and place in container for disposal, according to local regulations. To the extent possible cleaning is performed with normal cleaning agents. Avoid use of solvents.

Special spill response procedures

- If a spill/release in excess of the EPA reportable quantity is made into the environment, immediately notify the national response center in the United States (phone: 1-800-424-8802).
 - US CERCLA Reportable quantity (RQ): None reportable.

SECTION 7. HANDLING AND STORAGE

Precautions for safe handling

: Smoking, storage of tobacco, consumption and storage of food or liquids are not allowed in the workrooms. See section on 'Exposure controls/personal protection' for information on personal protection.

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] SDS Revision Date (mm/dd/yyyy): 10/29/2021

SAFETY DATA SHEET

Conditions for safe storage	:	Store in a cool, dry, well-ventilated area. Containers that have been	n opened must
-		be carefully resealed and kept upright to prevent leakage. Store in o	original
		containers. Inspect periodically for damage or leaks. Store between	n: 2 and 8 °C (
		36 and 46°F)	
Incompatible materials	:	Strong oxidizing agents Strong reducing agents strong acids and base	es.

SECTION 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Limits:				
Chemical Name	ACGI	<u>H TLV</u>	<u>OSH</u>	<u>A PEL</u>
	TWA	<u>STEL</u>	PEL	<u>STEL</u>
Lyophilized N8-GP and excipients	N/Av	N/Av	N/Av	N/Av

Exposure controls

Ventilation and engineering measures

Ventilation and engineering		
	Provide sufficient mechanical ventilation (general and/or local exhaust) to keep the airborn concentrations of vapors, mists, aerosols or dust below their respective occupational exposure limits	
Respiratory protection	Respiratory protection is required if the concentrations exceed the TLV. Use a NIOSH approved dust respirator if dust levels exceed exposure limits. Seek advice from respiratory protection specialists.	
Skin protection	Wear protective gloves. The suitability for a specific workplace should be discussed with the producers of the protective gloves.	
Eye / face protection	Wear as appropriate: Safety glasses with side shields	
Other protective equipment	Wear appropriate protective clothing to prevent skin contact, such as coveralls or long sleeved shirt, long pants, and shoes and socks. Wear protective gloves. An eyewash station and safety shower should be made available in the immediate working area. Other equipment may be required depending on workplace standards.	ļ
General hygiene considerati	S	
	Avoid breathing dust. Avoid contact with skin, eyes and clothing. Do not eat, drink, smoke or use cosmetics while working with this product. Upon completion of work, wash hands before eating, drinking, smoking or use of toilet facilities. Remove soiled clothing and wash it thoroughly before reuse.	

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	granular
Odour	:	No data available.
Odour threshold	:	No data available.
рН	:	No data available.
Melting Point/Freezing point	:	No data available.
Initial boiling point and boilin	ıg I	range
	:	No data available.
Flash point	:	No data available.
Flashpoint (Method)	:	No data available.
Evaporation rate (BuAe = 1)	:	No data available.
Flammability (solid, gas)	:	The product is not flammable.
Lower flammable limit (% by	vo	l.)
	:	No data available.
Upper flammable limit (% by	vo	l.)
	:	No data available.
Oxidizing properties	:	None known.
Explosive properties	:	Not explosive
Vapour pressure	:	No data available.

Vanaur danaitu		No data available.	
Vapour density	-		
Relative density / Specific gra	Relative density / Specific gravity		
	:	No data available.	
Solubility in water	:	Soluble	
Other solubility(ies)	:	No data available.	
Partition coefficient: n-octane	ol/	water or Coefficient of water/oil distribution	
	:	No data available.	
Auto-ignition temperature	:	No data available.	
Decomposition temperature	:	No data available.	
Viscosity	:	No data available.	
Volatiles (% by weight)	:	No data available.	
Volatile organic Compounds (VOC's)			
	:	No data available.	
Absolute pressure of container			
	:	No data available.	
Flame projection length	:	No data available.	
Other physical/chemical com	m	ents	
	:	No additional information.	

SECTION 10. STABILITY AND REACTIVITY

Reactivity	: Not normally reactive.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous rea	ctions
	: Hazardous polymerization does not occur.
Conditions to avoid	: Frost
Incompatible materials	: Avoid contact with incompatible materials. Incompatible materials (see Section 7).
Hazardous decomposition	products
	News law sum, as fan ta berendeurs, samshursting and dusts in Ossiting 5

: None known, refer to hazardous combustion products in Section 5.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:

Routes of entry inhalation	:	YES
Routes of entry skin & eye	:	YES

Routes of entry Ingestion : YES

Routes of exposure skin absorption

: NO

Potential Health Effects:

Signs and symptoms of short-term (acute) exposure

 Sign and symptoms Inhalation
 : May cause mild transient irritation.

 Sign and symptoms ingestion
 : Ingestion may cause gastrointestinal irritation, nausea, vomiting and diarrhea.

 Sign and symptoms skin
 : May cause mild skin irritation on prolonged contact.

 Sign and symptoms eyes
 : Direct eye contact may cause slight redness.

 Potential Chronic Health Effects
 : Prolonged exposure can cause redness, swelling, itching, cracking of the skin, dermatitis and sensitization.

 Mutagenicity
 : Not expected to be mutagenic in humans.

 Carcinogenicity
 : No components are listed as carcinogens by ACGIH, IARC, OSHA or NTP.

Reproductive effects 8	Teratogenicity
-------------------------------	----------------

Sensitization to material	 Not expected to have other reproductive effects. Not expected to be a skin or respiratory sensitizer.
Specific target organ effects	: The substance or mixture is not classified as specific target organ toxicant, single exposure.
	The substance or mixture is not classified as specific target organ toxicant, repeated exposure.
Medical conditions aggravat	ed by overexposure
	: Pre-existing skin, eye and respiratory disorders.
Synergistic materials	: No information available.
Toxicological data	: There is no available data for the product itself, only for the ingredients. See below for individual ingredient acute toxicity data.

	LC₅₀(4hr)	LD ₅₀		
<u>Chemical name</u>	<u>inh, rat</u>	<u>(Oral, rat)</u>	<u>(Rabbit, dermal)</u>	
Lyophilized N8-GP and excipients	N/Av	N/Av	N/Av	

Other important toxicological hazards

: See Section 3 for additional information.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity : Discharge into the environment must be avoided. The product should not be allowed to enter drains or water courses, or be deposited where it can affect ground or surface waters.

See the following tables for individual ingredient ecotoxicity data.

Ecotoxicity data:

Ingredients	040#	Toxicity to Fish				
	CAS #	LC50 / 96h	NOEC / 21 day	M Factor		
Lyophilized N8-GP and excipients	N/Av	N/Av	N/Av	None.		

Ingredients	CAS #	icity to Daphnia			
		EC50 / 48h	NOEC / 21 day	M Factor	
Lyophilized N8-GP and excipients	N/Av	N/Av	N/Av	None.	

Ingredients	CAS #	Toxicity to Algae				
		EC50 / 96h or 72h	NOEC / 96h or 72h	M Factor		
Lyophilized N8-GP and excipients	N/Av	N/Av	N/Av	None.		

Persistence and degradability

: No data is available on the product itself.

Bioaccumulation potential

: No data is available on the product itself.

Page 6 of 8

SAFETY DATA SHEET

<u>Components</u>	Partition coefficient n-octanol/water (log Kow)	Bioconcentration factor (BCF)					
Lyophilized N8-GP and excipients (CAS N/Av)	N/Av	N/Av					
Mobility in soil	: No data is available on the product itself.						
Other Adverse Environme	ntal effects						
	: No data is available on the product itself.						
SECTION 13. DISPOSAL	CONSIDERATIONS						
Handling for Disposal	: Handle waste according to recommendations in Se contain hazardous residues.	ection 7. Empty containers may					
Methods of Disposal	: Dispose in accordance with all applicable federal, regulations.	: Dispose in accordance with all applicable federal, state, provincial and local regulations.					
RCRA	: If this product, as supplied, becomes a waste in the criteria of a hazardous waste as defined under RC responsibility of the waste generator to determine disposal method.	RA, Title 40 CFR 261. It is the					

SECTION 14. TRANSPORT INFORMATION

Regulatory Information	UN Number	UN proper shipping name	Transport hazard class(es)	Packing Group	Label
49CFR/DOT	None.	Not regulated.	not regulated	none	\bigotimes
49CFR/DOT Additional information	None.				
ICAO/IATA	None.	Not regulated.	not regulated	none	\bigotimes
ICAO/IATA Additional information	None.	<u> </u>	!		
IMDG	None.	Not regulated.	not regulated	none	\bigotimes
IMDG Additional information	None.	1			

Environmental hazards

: This product does not meet the criteria for an environmentally hazardous mixture, according to the IMDG Code. See Section 12 for more environmental information. Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

: This information is not available.

SECTION 15 - REGULATORY INFORMATION

US Federal Information:

Components listed below are present on the following U.S. Federal chemical lists:

	TSCA Reportab		CERCLA Reportable	SARA TITLE III: Sec. 302, Extremely	SARA TITLE III: Sec. 313, 40 CFR 372, Specific Toxic Chemical		
	Inventory	Quantity(RQ) (40 CFR 117.302):	Hazardous Substance, 40 CFR 355:	Toxic Chemical	de minimus Concentration		
Lyophilized N8-GP and excipients	N/Av	NL	None.	None.	No	N/Ap	

SARA TITLE III: Sec. 311 and 312, SDS Requirements, 40 CFR 370 Hazard Classes: None.

US State Right to Know Laws:

The following chemicals are specifically listed by individual States:

Ingredients	CAS #	California Proposition 65		State "Right to Know" Lists					
		Listed	Type of Toxicity	CA	MA	MN	NJ	PA	RI
Lyophilized N8-GP and excipients	N/Av	No	N/Ap	Yes	Yes	Yes	Yes	Yes	Yes

Canadian Information:

WHMIS information: Refer to Section 2 for a WHMIS Classification for this product.

International Information:

Components listed below are present on the following International Inventory list:

Ingredients	CAS #	European EINECs	Australia AICS	Philippines PICCS	Japan ENCS	Korea KECI/KECL	China IECSC	NewZealand IOC
Lyophilized N8-GP and excipients	N/Av		N/Av	N/Av	N/Av	N/Av	N/Av	N/Av

SECTION 16. OTHER INFORMATION

Legend	 ACGIH: American Conference of Governmental Industrial Hygienists CAS: Chemical Abstract Services CERCLA: Comprehensive Environmental Response, Compensation, and Liability Act of 1980 CFR: Code of Federal Regulations CNS: Central Nervous System DOT: Department of Transportation EPA: Environmental Protection Agency IARC: International Agency for Research on Cancer IMDG: International Maritime Dangerous Goods Inh: Inhalation LC: Lethal Concentration LD: Lethal Dose N/Ap: Not Applicable N/Av: Not Available NTP: National Toxicology Program OSHA: Occupational Safety and Health Administration PEL: Permissible exposure limit SARA: Superfund Amendments and Reauthorization Act STEL: Short Term Exposure Limit TDG: Canadian Transportation of Dangerous Goods Act & Regulations TLV: Threshold Limit Values TWA: Time Weighted Average
	WHMIS: Workplace Hazardous Materials Identification System

Page 8 of 8

SAFETY DATA SHEET

References Preparation Date (mm/dd/yyy Reviewed Date SDS (dd/mm/	: 07/19/2019
Revision No. Revision Information Other special considerations	 29/10/2021 2 (M)SDS sections updated :2. HAZARDS IDENTIFICATION for handling Provide adequate information, instruction and training for operators.
Prepared for: Novo Nordisk 800 Scudders Mill Road Plainsboro, NJ 08536	

Telephone: 1-800-727-6500 www.novonordisk-us.com

Prepared by:

ICC The Compliance Center Inc. Telephone: (888) 442-9628 (U.S.): (888) 977-4834 (Canada) http://www.thecompliancecenter.com



DISCLAIMER

This Safety Data Sheet was prepared by ICC The Compliance Center Inc. using information provided by Novo Nordisk and CCOHS' Web Information Service. The information in the Safety Data Sheet is offered for your consideration and guidance when exposed to this product. ICC The Compliance Center Inc and Novo Nordisk expressly disclaim all expressed or implied warranties and assume no responsibilities for the accuracy or completeness of the data contained herein. The data in this SDS does not apply to use with any other product or in any other process.

This Safety Data Sheet may not be changed, or altered in any way without the expressed knowledge and permission of ICC The Compliance Center Inc. and Novo Nordisk.

END OF DOCUMENT